---
title: "CSPC Reports Nine-Month Revenue and Profit Growth in 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305914128.md"
description: "CSPC Pharmaceutical Group reported strong nine-month results for 2026, with unaudited revenue reaching RMB25.26 billion, a 27% year-on-year increase. Profit attributable to shareholders surged 101.5% to RMB7.076 billion, driven by a 40.1% rise in finished-drug revenue to RMB21.648 billion, largely due to higher license fee income and steady pharmaceutical sales growth."
datetime: "2026-11-18T04:38:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305914128.md)
  - [en](https://longbridge.com/en/news/305914128.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305914128.md)
generator: "portal-rs"
---

# CSPC Reports Nine-Month Revenue and Profit Growth in 2026

An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.

During the nine months ended 30 September 2026, CSPC recorded unaudited revenue of RMB25,260 million, up 27.0% from a year earlier, while reported profit attributable to shareholders rose 101.5% to RMB7,076 million. Basic earnings per share increased 102.3% to RMB62.14 cents.

Underlying profit, before fair value changes on financial assets measured at FVTPL and employee share-based compensation expense, rose 134.5% to RMB7,220 million. Finished-drug revenue increased 40.1% to RMB21,648 million, including RMB6,268 million in licence fee income, with the increase mainly due to higher licence fee income and steady growth in pharmaceutical product sales.

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [CSPC Pharmaceutical Group: Revenue, licensing income and pipeline milestones advanced alongside a 73.6% 1-9M gross margin](https://longbridge.com/en/news/305926514.md)
- [CSPC Starts Phase I/II Trial of SYS6055 for B-Cell Non-Hodgkin Lymphoma in China](https://longbridge.com/en/news/304626206.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [CSPC’s Anbenitamab Regimen Cuts Death Risk 61% in Phase III Gastric Cancer Trial](https://longbridge.com/en/news/303074350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**